Trial
NCT03861403
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Leap Therapeutics, Inc.
Collaborators
Pfizer; Merck KGaA, Darmstadt, Germany
Condition
Solid Tumors
Intervention
TRX518
Why stopped
Product development discontinued unrelated to safety.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-30